Lineage Cell Therapeutics Inc [AMEX: LCTX] gained 6.48% or 0.07 points to close at $1.15 with a heavy trading volume of 3699407 shares.
It opened the trading session at $1.06, the shares rose to $1.18 and dropped to $1.03, the range by which the price of stock traded the whole day. The daily chart for LCTX points out that the company has recorded 70.37% gains over the past six months.
If we look at the average trading volume of 2.26M shares, LCTX reached to a volume of 3699407 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Lineage Cell Therapeutics Inc [LCTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LCTX shares is $3.92 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LCTX stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Craig Hallum have made an estimate for Lineage Cell Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 20, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on November 02, 2022, representing the official price target for Lineage Cell Therapeutics Inc stock. Previously, the target price had yet another raise to $4, while B. Riley Securities analysts kept a Buy rating on LCTX stock.
The Price to Book ratio for the last quarter was 3.32, with the Price to Cash per share for the same quarter was set at 0.21.
Trading performance analysis for LCTX stock
Lineage Cell Therapeutics Inc [LCTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.16. With this latest performance, LCTX shares gained by 6.48% in over the last four-week period, additionally plugging by 70.37% over the last 6 months – not to mention a rise of 128.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LCTX stock in for the last two-week period is set at 66.91, with the RSI for the last a single of trading hit 0.0952, and the three-weeks RSI is set at 0.0880 for Lineage Cell Therapeutics Inc [LCTX]. The present Moving Average for the last 50 days of trading for this stock 0.8200, while it was recorded at 1.0170 for the last single week of trading, and 0.6669 for the last 200 days.
Lineage Cell Therapeutics Inc [LCTX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Lineage Cell Therapeutics Inc [LCTX] shares currently have an operating margin of -223.10% and a Gross Margin at 90.90%. Lineage Cell Therapeutics Inc’s Net Margin is presently recorded at -169.57%.
Lineage Cell Therapeutics Inc (LCTX) Capital Structure & Debt Analysis
According to recent financial data for Lineage Cell Therapeutics Inc. ( LCTX), the Return on Equity (ROE) stands at -21.40%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -14.72%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Lineage Cell Therapeutics Inc’s Return on Invested Capital (ROIC) is -20.23%, showcasing its effectiveness in deploying capital for earnings.
Lineage Cell Therapeutics Inc (LCTX) Efficiency & Liquidity Metrics
Based on Lineage Cell Therapeutics Inc’s (LCTX) latest financial statements, the Debt-to-Equity Ratio is 0.03%, indicating its reliance on debt financing relative to shareholder equity.
Lineage Cell Therapeutics Inc (LCTX) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Lineage Cell Therapeutics Inc. (LCTX) effectively leverages its workforce, generating an average of -$210519.48 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.82% and a Quick Ratio of 3.82%, indicating strong ability to cover short-term liabilities.
Lineage Cell Therapeutics Inc [LCTX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LCTX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Lineage Cell Therapeutics Inc go to 9.01%.
An analysis of Institutional ownership at Lineage Cell Therapeutics Inc [LCTX]
There are presently around $47.89%, or 48.09% of LCTX stock, in the hands of institutional investors. The top three institutional holders of LCTX stocks are: BROADWOOD CAPITAL INC with ownership of 41.67 million shares, which is approximately 22.0675%. BLACKROCK INC., holding 9.56 million shares of the stock with an approximate value of $$9.53 million in LCTX stocks shares; and BLACKROCK INC., currently with $$8.45 million in LCTX stock with ownership which is approximately 4.488%.
